Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment

Tae Heung Kang, Jung Hwa Park, Andrew Yang, Hyun Jin Park, Sung Eun Lee, Young Seob Kim, Gun Young Jang, Emily Farmer, Brandon Lam, Yeong Min Park, Chien Fu Hung

Research output: Contribution to journalArticle

Abstract

The interaction between immune cells and phosphatidylserine (PS) molecules exposed on the surface of apoptotic-tumor bodies, such as those induced by chemotherapies, contributes to the formation of an immunosuppressive tumor microenvironment (TME). Annexin A5 (AnxA5) binds with high affinity to PS externalized by apoptotic cells, thereby hindering their interaction with immune cells. Here, we show that AnxA5 administration rescue the immunosuppressive state of the TME induced by chemotherapy. Due to the preferential homing of AnxA5 to the TME enriched with PS+ tumor cells, we demonstrate in vivo that fusing tumor-antigen peptide to AnxA5 significantly enhances its immunogenicity and antitumor efficacy when administered after chemotherapy. Also, the therapeutic antitumor effect of an AnxA5-peptide fusion can be further enhanced by administration of other immune checkpoint inhibitors. Our findings support the administration of AnxA5 following chemotherapy as a promising immune checkpoint inhibitor for cancer treatment.

Original languageEnglish (US)
Article number1137
JournalNature communications
Volume11
Issue number1
DOIs
StatePublished - Dec 1 2020

    Fingerprint

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Kang, T. H., Park, J. H., Yang, A., Park, H. J., Lee, S. E., Kim, Y. S., Jang, G. Y., Farmer, E., Lam, B., Park, Y. M., & Hung, C. F. (2020). Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nature communications, 11(1), [1137]. https://doi.org/10.1038/s41467-020-14821-z